A Study to Investigate the Effect of MEDI0382 on Hepatic Glycogen Metabolism in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.
MedImmune LLC · Type 2 Diabetes Mellitus
Phase 2
Completed
51
2024-11
Industry sponsor intelligence
MedImmune LLCClinical Pipeline.
Lead-sponsor view of MedImmune LLC's indexed peptide studies, development phases, active programs, completed work and recent registry changes.
- Total
- 15
- Recruiting
- 0
- Active
- 0
- Completed
- 15
- Results posted
- 8
- Avg enrollment
- 67
Pipeline overview
Programs by phase and activity.
Velocity
MedImmune LLC trials by start year
Study start year · indexed snapshot
Development
Trials by phase
16phase labels
Early Phase 10
Phase 18
Phase 28
Phase 30
Phase 40
| Product | Studies | Early / I | Phase II | Phase III | Phase IV | Active |
|---|---|---|---|---|---|---|
| Cotadutide → | 15 | 8 | 8 | 0 | 0 | 0 |
| Liraglutide → | 1 | 0 | 1 | 0 | 0 | 0 |
Active peptide trials
In motion now.
No studies in this snapshot.
Completed trials
Finished registry records.
NCT IDStudyPhase / statusEnrollmentUpdated
A Study to Evaluate the Effect of MEDI0382 on Energy Balance in Overweight and Obese Participants With Type 2 Diabetes Mellitus
MedImmune LLC · Diabetes Mellitus, Type II · Obesity
Phase 2
Completed
28
2023-01
A Study to Evaluate Safety and Pharmacodynamic Efficacy of 0382 in Obese Subjects With NAFLD/NASH.
MedImmune LLC · Non-alcoholic Fatty Liver Disease (NAFLD) · Non-alcoholic Steatohepatitis (NASH)
Phase 2
Completed
74
2023-01
A Study to Assess Safety, Tolerability, and Pharmacokinetics of MEDI0382 in Non-diabetic Obese Participants
MedImmune LLC · Obesity
Phase 1
Completed
51
2021-08
A Study to Evaluate the Safety and Tolerability of MEDI0382 in Overweight and Obese Participants With Type 2 Diabetes Mellitus
MedImmune LLC · Type 2 Diabetes Mellitus
Phase 2
Completed
20
2020-06
A Study to Look at the Effect MEDI0382 Has on Blood Sugar in People With Type 2 Diabetes and Kidney Problems and Also to Check That MEDI0382 is Well Tolerated
MedImmune LLC · Type II Diabetes Mellitus · Renal Insufficiency
Phase 2
Completed
41
2020-04
A Study Investigating the Pharmacokinetics of a Single Dose Administration of Cotadutide
MedImmune LLC · Type 2 Diabetes Mellitus
Phase 1
Completed
36
2020-04
Study of MEDI0382 in Combination With Dapagliflozin and Metformin in Overweight/Obese Participants With Type 2 Diabetes
MedImmune LLC · Type 2 Diabetes Mellitus
Phase 2
Completed
49
2020-01
A Study to Investigate Different Doses of 0382 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.
MedImmune LLC · Type 2 Diabetes Mellitus
Phase 2
Completed
65
2019-11
A Study to Evaluate the Safety and Pharmacokinetics of MEDI0382 in Overweight/Obese Subjects of Japanese or Chinese Descent
MedImmune LLC · Safety · Healthy Subjects
Phase 1
Completed
32
2019-04
Showing 10 of 15 studies
Search sponsor records
All MedImmune LLC studies.
This page groups studies where MedImmune LLC is listed as the lead industry sponsor. Collaborator-only records are not included in the count.
15 matching studies
Last registry update first
Recent updates
Latest registry movement.
NCT03555994A Study to Investigate the Effect of MEDI0382 on Hepatic Glycogen Metabolism in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.Nov 12, 2024NCT03596177A Study to Evaluate the Effect of MEDI0382 on Energy Balance in Overweight and Obese Participants With Type 2 Diabetes MellitusJan 19, 2023NCT04019561A Study to Evaluate Safety and Pharmacodynamic Efficacy of 0382 in Obese Subjects With NAFLD/NASH.Jan 17, 2023NCT03625778A Study to Assess Safety, Tolerability, and Pharmacokinetics of MEDI0382 in Non-diabetic Obese ParticipantsAug 23, 2021NCT03745937A Study to Evaluate the Safety and Tolerability of MEDI0382 in Overweight and Obese Participants With Type 2 Diabetes MellitusJun 5, 2020NCT03550378A Study to Look at the Effect MEDI0382 Has on Blood Sugar in People With Type 2 Diabetes and Kidney Problems and Also to Check That MEDI0382 is Well ToleratedApr 13, 2020NCT04091373A Study Investigating the Pharmacokinetics of a Single Dose Administration of CotadutideApr 7, 2020NCT03444584Study of MEDI0382 in Combination With Dapagliflozin and Metformin in Overweight/Obese Participants With Type 2 DiabetesJan 13, 2020NCT03244800A Study to Investigate Different Doses of 0382 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.Nov 19, 2019NCT03385369A Study to Evaluate the Safety and Pharmacokinetics of MEDI0382 in Overweight/Obese Subjects of Japanese or Chinese DescentApr 16, 2019